Equidacent®
ACTIVE PRINCIPLE:
bevacizumab
INDICATION:
Colorectal cancer
Breast cancer
Ovarian cancer
Non-small cell lung carcinoma
Renal cell carcinoma
DATE:
29/12/2020
STATUS:
Authorized
ACTIVE PRINCIPLE:
bevacizumab
INDICATION:
Colorectal cancer
Breast cancer
Ovarian cancer
Non-small cell lung carcinoma
Renal cell carcinoma
DATE:
29/12/2020
STATUS:
Authorized